WT1 expression encompasses both hematopoietic and solid tumors and therefore, a TCRm targeting this oncoprotein should have a broad application as a therapeutic agent against a variety of human leukemias, myeloma and solid tumors (226, 232). Here, WT1 is linked to leukemia.